Scholar Rock Holding (SRRK) Free Cash Flow (2017 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly Free Cash Flow of -$82.2 million in Q1 2026, down 8.79% quarter-over-quarter from -$75.5 million in Q4 2025, and down 4.08% on a YoY basis from -$85.7 million in Q1 2025.
Scholar Rock Holding (SRRK) Free Cash Flow (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Free Cash Flow history runs 10 years deep, the most recent figure standing at -$82.2 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 4.08% year-over-year to -$82.2 million; the TTM figure through Mar 2026 stood at -$303.9 million (down 32.0% YoY), while the FY2025 annual figure was -$300.6 million, down 49.54% from the prior year.
- Free Cash Flow was -$82.2 million for Q1 2026 at Scholar Rock Holding, down from -$75.5 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$25.7 million in Q3 2022 to a low of -$82.2 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$50.8 million across 5 years, with a median of -$49.2 million in 2024.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow surged 35.89% in 2022, then sank 62.63% in 2024.
- A 5-year view of Free Cash Flow shows it stood at -$29.9 million in 2022, then decreased by 25.08% to -$37.3 million in 2023, then slumped by 32.63% to -$49.5 million in 2024, then tumbled by 52.47% to -$75.5 million in 2025, then declined by 8.79% to -$82.2 million in 2026.
- The last three Free Cash Flow figures came in at -$82.2 million (Q1 2026), -$75.5 million (Q4 2025), and -$69.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - | -82.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -82.17 Mn |
| Mar 31, 2026 | -82.17 Mn |
| Dec 31, 2025 | -75.53 Mn |
| Dec 31, 2025 | -75.53 Mn |
| Sep 30, 2025 | -69.01 Mn |
| Sep 30, 2025 | -69.01 Mn |
| Jun 30, 2025 | -77.16 Mn |
| Jun 30, 2025 | -77.16 Mn |
| Mar 31, 2025 | -78.95 Mn |
| Mar 31, 2025 | -78.95 Mn |
| Dec 31, 2024 | -49.54 Mn |
| Dec 31, 2024 | -49.54 Mn |
| Sep 30, 2024 | -52.49 Mn |
| Sep 30, 2024 | -52.49 Mn |
| Jun 30, 2024 | -49.23 Mn |
| Jun 30, 2024 | -49.23 Mn |
| Mar 31, 2024 | -49.80 Mn |
| Mar 31, 2024 | -49.80 Mn |
| Dec 31, 2023 | -37.35 Mn |
| Dec 31, 2023 | -37.35 Mn |